Igor Puzanov, MD, MSCI, FACP
In 2015, talimogene laherparepvec (T-VEC; Imlygic) became the first in-class oncolytic immunotherapy to be FDA approved for the treatment of advanced-stage unresectable melanoma, but its path forward may be in combination with checkpoint inhibitors, explained Igor Puzanov, MD, MSCI, FACP.
, Puzanov, director of the Early Phase Clinical Trials Program, chief of Melanoma, co-leader, CCSG Experimental Therapeutics Program, professor of oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, discussed the current and potential future utility of T-VEC in patients with advanced-stage melanoma.
OncLive®: What is T-VEC and how does it differ from other immunotherapies?
: T-VEC is a drug dear to my heart; I helped develop it since 2009. T-VEC is an oncolytic virus. The basis of T-VEC is the herpes simplex virus, which is a virus that everybody is exposed to. The researchers modified it, so it cannot infect healthy cells; it can only infect the tumor cells of not just melanoma, but other [malignant cells].
... to read the full story